PTHS
AMEXPelthos Therapeutics Inc.
News · 26 weeks55-14%
2025-12-142026-06-07
Mix3590d
- Insider16(46%)
- SEC Filings9(26%)
- Other6(17%)
- Earnings3(9%)
- Analyst1(3%)
Latest news
25 items- SECPelthos Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Pelthos Therapeutics Inc. (0001919246) (Filer)
- PRPelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare ConferenceDURHAM, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, ("Pelthos"), today announced that CEO Scott Plesha will present at 11:05 am ET and participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference on June 4, 2026 in New York. Investors interested in arranging one-on-one meetings should contact their Jefferies representative. About Pelthos Therapeutics Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease prod
- INSIDERCFO, Treas & Secty Francis Knuettel Ii returned 13,947 shares to the company and sold $40,265 worth of shares (1,500 units at $26.84), decreasing direct ownership by 42% to 19,525 units (SEC Form 4)4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
- SECSEC Form 144 filed by Pelthos Therapeutics Inc.144 - Pelthos Therapeutics Inc. (0001919246) (Subject)
- SECPelthos Therapeutics Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Leadership Update, Financial Statements and Exhibits8-K - Pelthos Therapeutics Inc. (0001919246) (Filer)
- INSIDERDirector Friedberg Ezra M covered exercise/tax liability with 144 shares, decreasing direct ownership by 0.18% to 81,883 units (SEC Form 4) (withholding obligation)4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Pelthos Therapeutics Inc.SCHEDULE 13G/A - Pelthos Therapeutics Inc. (0001919246) (Subject)
- SECPelthos Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Pelthos Therapeutics Inc. (0001919246) (Filer)
- SECSEC Form 10-Q filed by Pelthos Therapeutics Inc.10-Q - Pelthos Therapeutics Inc. (0001919246) (Filer)
- PRPelthos Therapeutics Announces First Quarter 2026 Financial ResultsZELSUVMI® net product revenue grew 17% quarter over quarter from $9.1 million in the fourth quarter of 2025 to $10.7 million in the first quarter of 2026 7,884 ZELSUVMI units prescribed by 3,228 unique prescribers for the first quarter of 2026, with a 25% quarter over quarter increase in units dispensed Management will host a conference call today, May 14, 2026, at 8:30 a.m. ET DURHAM, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos," "we" or the "Company"), today announced its financial results for the first quarter ended March 31,
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Pelthos Therapeutics Inc.SCHEDULE 13G/A - Pelthos Therapeutics Inc. (0001919246) (Subject)
- PRPelthos Therapeutics to Report First Quarter 2026 Financial Results on May 14, 2026DURHAM, N.C., May 01, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today announced it will report first quarter 2026 financial results on Thursday, May 14, 2026. The company will hold a conference call followed by a question-and-answer period at 8:30 a.m. Eastern time. Details for the conference call can be found below: Date: Thursday, May 14, 2026Time: 8:30 a.m. Eastern TimeToll Free: 1-877-451-6152International: 1-201-389-0879Conf. ID: 13760399 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1761761&tp_key=d31924f2e0 About Peltho
- INSIDERSEC Form 3 filed by new insider Gay John M.3 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
- SECPelthos Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Pelthos Therapeutics Inc. (0001919246) (Filer)
- PRPelthos Therapeutics to Participate in Piper Sandler Spring Biopharma SymposiumDURHAM, N.C., April 14, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today announced that CEO Scott Plesha will participate in one-on-one investor meetings at the Piper Sandler Spring Biopharma Symposium on April 16, 2026 in Boston. Investors interested in arranging one-on-one meetings should contact their Piper Sandler representative.About Pelthos TherapeuticsPelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease products that address unmet
- PRPelthos Therapeutics Announces CFO TransitionDURHAM, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today announced John M. Gay has been appointed Chief Financial Officer effective April 10, 2026. Mr. Gay succeeds Francis Knuettel II, who served as Pelthos' Chief Financial Officer since July 2025. "John played a key role in helping us establish and launch Pelthos. He is an experienced financial leader, and we are excited to have him step into this new role as we continue our strong commercial momentum and enter the next phase of the company's growth," said Scott Plesha, CEO of
- SECPelthos Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Pelthos Therapeutics Inc. (0001919246) (Filer)
- INSIDERSEC Form 4 filed by Malamut Richard4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
- INSIDERSEC Form 4 filed by Friedberg Ezra M4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
- INSIDERSEC Form 4 filed by Pauls Matthew4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
- INSIDERSEC Form 4 filed by Greenleaf Peter4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Friedberg Ezra M4/A - Pelthos Therapeutics Inc. (0001919246) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Davis Todd C4/A - Pelthos Therapeutics Inc. (0001919246) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Malamut Richard4/A - Pelthos Therapeutics Inc. (0001919246) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Plesha Scott M.4/A - Pelthos Therapeutics Inc. (0001919246) (Issuer)
PTHS FAQ
6 questionsWhere does PTHS stock trade?
Pelthos Therapeutics Inc. (PTHS) is listed on AMEX.What sector and industry is PTHS in?
Pelthos Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Pelthos Therapeutics Inc. go public?
Pelthos Therapeutics Inc. (PTHS) completed its IPO in 2024.What are analysts saying about PTHS?
Pelthos Therapeutics Inc. has had 6 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight on 2026-04-01. Recent price targets cluster around $4800.00.What companies are similar to PTHS?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare PTHS side-by-side with any of them on Quantisnow.How can I track PTHS on Quantisnow?
Quantisnow aggregates Pelthos Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PTHS to receive live email and push alerts on every new disclosure.